India’s Laurus Labs Ltd. says it is expanding its current capacities for key active pharmaceutical ingredients to meet increasing demand for third-party API sales, after the company saw an “extraordinary year” as it reported a 70% year on year jump in revenues to INR48.14bn ($652m) for its financial year ended 31 March 2021.
As Laurus registered a sales increase of INR19.81bn in a single financial year, founder and CEO Satyanarayana Chava also stated...




